German multinational pharmaceutical and life sciences company Bayer AG (ETR:BAYN) has opened a new Research and Innovation Center in the United States, the company announced on Wednesday.
Located at Kendall Square in Boston-Cambridge, Massachusetts, this 62,100 sq ft facility houses a new centre of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies.
In addition, a newly established research team will focus on leveraging chemical biology techniques to further advance the company's oncology drug development process.
Bayer's investment in the new facility amounts to USD140m.
Boston-Cambridge is home to approximately 1,000 biotechnology companies, with Kendall Square being the centre of pharmaceutical innovation on the East Coast of the US, Bayer said. The company is now present in four of the largest biotechnology hubs in the country: Boston, San Francisco, San Diego and Research Triangle Park, North Carolina.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates